During a live event, Shannon N. Westin, MD, MPH, and participants discussed their experience treating patients with ...

"Recurrent or metastatic cervical cancer is a devastating disease, and patients can face a difficult treatment journey with limited options," said Ignace Vergote, M.D., Ph.D., University Hospitals ...

Genmab has announced that the European Commission (EC) has approved Tivdak (tisotumab vedotin) to treat recurrent or metastatic cervical cancer.

TIVDAK® is the first and only antibody-drug conjugate (ADC) approved to treat recurrent or metastatic cervical cancer with disease progression on or after systemic therapy In the global Phase 3 ...

"Recurrent or metastatic cervical cancer is a devastating disease, and patients can face a difficult treatment journey with limited options,” said Ignace Vergote, M.D., Ph.D., University Hospitals ...

Emerging biotech leader AKESF develops Ivonescimab & Cadonilimab; while offering growth potential with US partnerships, ...